New method for delivering HIV treatment through skin and mouth
Official title: Ionic liquid-based nanoemulsion containing combination antiretroviral drugs for the oral and transdermal treatment of HIV infection
Funded at University of Arizona · NIH-10836933 · Data updated 2026-11-12
This study is looking at a new way to deliver HIV medications using tiny droplets in a special liquid, which could make the treatment work better and have fewer side effects, so patients might find it easier and safer to stick to their therapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | September 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $208,575 |
| NIH project number | 1R21AI181603-01 |
| Project ID | NIH-10836933 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living with HIV who are currently on antiretroviral therapy or are in need of effective treatment options.
✕Less likely to help
Patients who are not living with HIV or those who are already effectively managing their condition with existing therapies may not benefit from this research.
What this research studies
This research investigates a novel approach to delivering a combination of antiretroviral drugs for HIV treatment using ionic liquid-based nanoemulsions. The goal is to enhance the effectiveness and reduce side effects of existing oral medications by improving their bioavailability and allowing for non-invasive transdermal administration. Patients may benefit from a more convenient and potentially safer method of receiving their HIV therapy, which could lead to better adherence and outcomes. The study will explore how these new formulations can be developed and tested for their effectiveness in treating HIV.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and less invasive way to manage their HIV treatment.
How similar studies have gone: While the use of ionic liquids in drug delivery is a novel approach, similar strategies have shown promise in enhancing drug bioavailability in other therapeutic areas.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Date, Abhijit a — University of Arizona
- Study coordinator: Date, Abhijit a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how genetic changes in blood cells relate to heart disease in people with HIV
A study will look at how age-related blood cell mutations and large chromosomal changes might contribute to heart disease risk in people living with HIV.
-
Cardiac health and protein markers in kids with perinatal HIV exposure or infection
A study from Duke aims to understand heart health and protein biomarkers in children who were exposed to or infected with HIV at birth, especially in sub-Saharan Africa.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.